Several groups have found that BRAF inhibitor-resistant melanoma cell lines can recover ERK phosphorylation independently of the presence of BRAF inhibitors, and the same remains true for the classic chemotherapeutic drug dacarbazine (DTIC) (11, 13, 17, 18, 20–24). Here, BRAF is linked to melanoma.